• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

正确框架的重要性:丝裂原活化蛋白激酶途径和支架蛋白 PTPIP51。

The Importance of the Right Framework: Mitogen-Activated Protein Kinase Pathway and the Scaffolding Protein PTPIP51.

机构信息

Institute of Anatomy and Cell Biology, Justus-Liebig-University, 35392 Giessen, Germany.

Institute of Pathology, Justus-Liebig-University, 35392 Giessen, Germany.

出版信息

Int J Mol Sci. 2018 Oct 22;19(10):3282. doi: 10.3390/ijms19103282.

DOI:10.3390/ijms19103282
PMID:30360441
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6213971/
Abstract

The protein tyrosine phosphatase interacting protein 51 (PTPIP51) regulates and interconnects signaling pathways, such as the mitogen-activated protein kinase (MAPK) pathway and an abundance of different others, e.g., Akt signaling, NF-κB signaling, and the communication between different cell organelles. PTPIP51 acts as a scaffold protein for signaling proteins, e.g., Raf-1, epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (Her2), as well as for other scaffold proteins, e.g., 14-3-3 proteins. These interactions are governed by the phosphorylation of serine and tyrosine residues of PTPIP51. The phosphorylation status is finely tuned by receptor tyrosine kinases (EGFR, Her2), non-receptor tyrosine kinases (c-Src) and the phosphatase protein tyrosine phosphatase 1B (PTP1B). This review addresses various diseases which display at least one alteration in these enzymes regulating PTPIP51-interactions. The objective of this review is to summarize the knowledge of the MAPK-related interactome of PTPIP51 for several tumor entities and metabolic disorders.

摘要

蛋白酪氨酸磷酸酶相互作用蛋白 51(PTPIP51)调节和相互连接信号通路,如丝裂原活化蛋白激酶(MAPK)通路和许多其他通路,如 Akt 信号通路、NF-κB 信号通路以及不同细胞细胞器之间的通讯。PTPIP51 作为信号蛋白的支架蛋白,如 Raf-1、表皮生长因子受体(EGFR)、人表皮生长因子受体 2(Her2),以及其他支架蛋白,如 14-3-3 蛋白。这些相互作用受 PTPIP51 丝氨酸和酪氨酸残基的磷酸化调控。磷酸化状态由受体酪氨酸激酶(EGFR、Her2)、非受体酪氨酸激酶(c-Src)和磷酸酶蛋白酪氨酸磷酸酶 1B(PTP1B)精细调节。本综述讨论了至少在这些调节 PTPIP51 相互作用的酶中存在一种改变的各种疾病。本综述的目的是总结 PTPIP51 与几种肿瘤实体和代谢紊乱相关的 MAPK 相关相互作用组的知识。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0320/6213971/2318e121e5df/ijms-19-03282-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0320/6213971/d4905e3082bb/ijms-19-03282-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0320/6213971/4f7410e7d0ad/ijms-19-03282-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0320/6213971/2318e121e5df/ijms-19-03282-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0320/6213971/d4905e3082bb/ijms-19-03282-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0320/6213971/4f7410e7d0ad/ijms-19-03282-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0320/6213971/2318e121e5df/ijms-19-03282-g003.jpg

相似文献

1
The Importance of the Right Framework: Mitogen-Activated Protein Kinase Pathway and the Scaffolding Protein PTPIP51.正确框架的重要性:丝裂原活化蛋白激酶途径和支架蛋白 PTPIP51。
Int J Mol Sci. 2018 Oct 22;19(10):3282. doi: 10.3390/ijms19103282.
2
Orchestrating cellular signaling pathways-the cellular "conductor" protein tyrosine phosphatase interacting protein 51 (PTPIP51).调控细胞信号通路——细胞“指挥家”蛋白酪氨酸磷酸酶相互作用蛋白51(PTPIP51)。
Cell Tissue Res. 2017 Jun;368(3):411-423. doi: 10.1007/s00441-016-2508-5. Epub 2016 Oct 12.
3
Crosstalks of the PTPIP51 interactome revealed in Her2 amplified breast cancer cells by the novel small molecule LDC3/Dynarrestin.新型小分子 LDC3/Dynarrestin 揭示 Her2 扩增型乳腺癌细胞中 PTPIP51 相互作用组的串扰。
PLoS One. 2019 May 10;14(5):e0216642. doi: 10.1371/journal.pone.0216642. eCollection 2019.
4
The known interactome of PTPIP51 in HaCaT cells—inhibition of kinases and receptors.已知 PTPIP51 在 HaCaT 细胞中的互作组——对激酶和受体的抑制作用。
Int J Biochem Cell Biol. 2014 Jan;46:19-31.
5
PTPIP51 in protein interactions: regulation and in situ interacting partners.PTPIP51 在蛋白质相互作用中的调节及其原位相互作用伙伴。
Cell Biochem Biophys. 2012 Jul;63(3):211-22. doi: 10.1007/s12013-012-9357-y.
6
PTPIP51 is phosphorylated by Lyn and c-Src kinases lacking dephosphorylation by PTP1B in acute myeloid leukemia.PTPIP51 可被 Lyn 和 c-Src 激酶磷酸化,而在急性髓系白血病中,PTP1B 缺乏对其去磷酸化作用。
Leuk Res. 2011 Oct;35(10):1367-75. doi: 10.1016/j.leukres.2011.03.024. Epub 2011 Apr 22.
7
Altered Protein Interactions of the Endogenous Interactome of PTPIP51 towards MAPK Signaling.PTPIP51内源性相互作用组对MAPK信号传导的蛋白质相互作用改变
Biomolecules. 2017 Jul 21;7(3):55. doi: 10.3390/biom7030055.
8
PTPIP51, a positive modulator of the MAPK/Erk pathway, is upregulated in glioblastoma and interacts with 14-3-3β and PTP1B in situ.PTPIP51 是 MAPK/Erk 通路的正向调节剂,在神经胶质瘤中上调,并与原位的 14-3-3β 和 PTP1B 相互作用。
Histol Histopathol. 2011 Dec;26(12):1531-43. doi: 10.14670/HH-26.1531.
9
PTPIP51—A New RelA-tionship with the NFκB Signaling Pathway.PTPIP51——与核因子κB信号通路的一种新关系。
Biomolecules. 2015 Apr 16;5(2):485-504. doi: 10.3390/biom5020485.
10
PTPIP51 levels in glioblastoma cells depend on inhibition of the EGF-receptor.胶质母细胞瘤细胞中的PTPIP51水平取决于表皮生长因子受体的抑制作用。
J Neurooncol. 2015 May;123(1):15-25. doi: 10.1007/s11060-015-1763-8. Epub 2015 Apr 11.

引用本文的文献

1
SHBs Mitigates Sorafenib-Induced Apoptosis in Hepatocellular Carcinoma via Activation of RAF1/MEK/ERK Signaling Pathway.SHBs通过激活RAF1/MEK/ERK信号通路减轻索拉非尼诱导的肝细胞癌凋亡。
Cancer Sci. 2025 Sep;116(9):2471-2485. doi: 10.1111/cas.70132. Epub 2025 Jun 28.
2
Serine-129 phosphorylated -synuclein drives mitochondrial dysfunction and calcium dysregulation in Parkinson's disease model.丝氨酸129磷酸化的α-突触核蛋白在帕金森病模型中导致线粒体功能障碍和钙调节异常。
Front Aging Neurosci. 2025 Mar 31;17:1538166. doi: 10.3389/fnagi.2025.1538166. eCollection 2025.
3
Bridging the gap: investigating the role of phosphorylation at the serine 129 site of α-synuclein in VAPB-PTPIP51 interactions.

本文引用的文献

1
Effectiveness of EGFR/HER2-targeted drugs is influenced by the downstream interaction shifts of PTPIP51 in HER2-amplified breast cancer cells.表皮生长因子受体(EGFR)/人表皮生长因子受体2(HER2)靶向药物的疗效受HER2扩增乳腺癌细胞中PTPIP51下游相互作用变化的影响。
Oncogenesis. 2018 Aug 24;7(8):64. doi: 10.1038/s41389-018-0075-1.
2
BRAF V600E mutation and BRAF VE1 immunoexpression profiles in different types of glioblastoma.不同类型胶质母细胞瘤中的BRAF V600E突变和BRAF VE1免疫表达谱
Oncol Lett. 2018 Aug;16(2):2402-2408. doi: 10.3892/ol.2018.8919. Epub 2018 Jun 6.
3
Improved Risk-Adjusted Survival for Melanoma Brain Metastases in the Era of Checkpoint Blockade Immunotherapies: Results from a National Cohort.
弥合差距:研究α-突触核蛋白丝氨酸129位点磷酸化在VAPB-PTPIP51相互作用中的作用。
Acta Neuropathol Commun. 2025 Feb 24;13(1):40. doi: 10.1186/s40478-025-01949-6.
4
Cannabinoids and PPAR Ligands: The Future in Treatment of Polycystic Ovary Syndrome Women with Obesity and Reduced Fertility.大麻素和过氧化物酶体增殖物激活受体配体:治疗肥胖和生育力降低多囊卵巢综合征女性的未来。
Cells. 2022 Aug 18;11(16):2569. doi: 10.3390/cells11162569.
5
The Emerging Role of Rab5 in Membrane Receptor Trafficking and Signaling Pathways.Rab5在膜受体运输和信号通路中的新兴作用
Biochem Res Int. 2020 Feb 11;2020:4186308. doi: 10.1155/2020/4186308. eCollection 2020.
6
Mitogen-Activated Protein Kinases: Functions in Signal Transduction and Human Diseases.丝裂原活化蛋白激酶:信号转导与人类疾病中的功能。
Int J Mol Sci. 2019 Sep 29;20(19):4844. doi: 10.3390/ijms20194844.
7
Reversal of sorafenib resistance in hepatocellular carcinoma: epigenetically regulated disruption of 14-3-3η/hypoxia-inducible factor-1α.肝细胞癌中索拉非尼耐药性的逆转:14-3-3η/缺氧诱导因子-1α的表观遗传调控破坏
Cell Death Discov. 2019 Jul 19;5:120. doi: 10.1038/s41420-019-0200-8. eCollection 2019.
免疫检查点阻断治疗时代黑素瘤脑转移的风险调整后生存率提高:一项全国性队列研究的结果。
Cancer Immunol Res. 2018 Sep;6(9):1039-1045. doi: 10.1158/2326-6066.CIR-18-0067. Epub 2018 Jul 12.
4
MEK inhibition may increase survival of NRAS-mutated melanoma patients treated with checkpoint blockade: Results of a retrospective multicentre analysis of 364 patients.MEK 抑制可能会增加接受检查点阻断治疗的NRAS 突变黑色素瘤患者的生存:对 364 名患者进行回顾性多中心分析的结果。
Eur J Cancer. 2018 Jul;98:10-16. doi: 10.1016/j.ejca.2018.04.010. Epub 2018 May 26.
5
Vemurafenib in Chinese patients with BRAF mutation-positive unresectable or metastatic melanoma: an open-label, multicenter phase I study.维莫非尼治疗中国 BRAF 突变阳性不可切除或转移性黑色素瘤患者的疗效:一项开放标签、多中心 I 期研究。
BMC Cancer. 2018 May 3;18(1):520. doi: 10.1186/s12885-018-4336-3.
6
Melanoma: What do all the mutations mean?黑色素瘤:所有这些突变意味着什么?
Cancer. 2018 Sep 1;124(17):3490-3499. doi: 10.1002/cncr.31345. Epub 2018 Apr 17.
7
Co-targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor-resistant melanoma.联合靶向 BET 和 MEK 作为 MAPK 和检查点抑制剂耐药黑色素瘤的挽救治疗。
EMBO Mol Med. 2018 May;10(5). doi: 10.15252/emmm.201708446.
8
Targeting FLT3 Mutations in Acute Myeloid Leukemia.靶向急性髓系白血病中的FLT3突变
Cells. 2018 Jan 8;7(1):4. doi: 10.3390/cells7010004.
9
Targeting c-KIT (CD117) by dasatinib and radotinib promotes acute myeloid leukemia cell death.达沙替尼和罗地替尼通过靶向 c-KIT(CD117)促进急性髓系白血病细胞死亡。
Sci Rep. 2017 Nov 10;7(1):15278. doi: 10.1038/s41598-017-15492-5.
10
Estimating progression-free survival in patients with glioblastoma using routinely collected data.使用常规收集的数据估计胶质母细胞瘤患者的无进展生存期。
J Neurooncol. 2017 Dec;135(3):621-627. doi: 10.1007/s11060-017-2619-1. Epub 2017 Sep 27.